A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis

The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.

Study Overview

• Status: Completed
• Conditions: Healthy; Dermatitis, Atopic
• Intervention / Treatment: Drug: LY3844583; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 102
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or; Phone Number: 1-317-615-4559; Email: ClinicalTrials.gov@lilly.com

Study Locations

• Japan
  • Osaka
    • Osaka-shi, Osaka, Japan, 532-0003
      • Medical Corporation Heishinkai OPHAC Hospital
  • Tokyo
    • Hachioji, Tokyo, Japan, 192-0071
      • P-One Clinic
• United States
  • California
    • Glendale, California, United States, 91206-4140
      • Parexel Early Phase Unit at Glendale

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy participants (Parts A and B):

  • Are male or female not of childbearing potential
  • inclusion of healthy Japanese participants, the participant must be first-generation Japanese, defined as the participant's biological parents and all of the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
  • inclusion of healthy Chinse participants, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China.
  • Must have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive. For healthy Japanese participants, have a body mass index of 18.0 to 28.0 kg/m², inclusive, and a body weight of 50 kg to 85 kg, inclusive.

• Atopic dermatitis participants (Part C):

  • Must have a body mass index of 18.0 to 45.0 kg/m², inclusive
  • Are male or female participants including those of child bearing potential
  • Must have a diagnosis of AD for at least 12 months with either poor response to topical treatments or inability to use topical treatments
  • Must agree to use moisturizer daily throughout the treatment period

Exclusion Criteria:

• All participants:

  • Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Have active or latent tuberculosis
  • Have had any cancer within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or metastatic disease within the 3 years prior to baseline
  • Have one of the following viral infections: hepatitis B virus, hepatitis C virus or human immunodeficiency virus.
  • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 30 days or 5 half-lives (whichever is longer) prior to dosing
  • Must not have previously completed a clinical trial with a molecule targeting interleukin-33 and/or the interleukin-33 receptor (ST2)
  • Are currently participating in or completed a clinical trial within the last 30 days
  • Have received a vaccine containing a live (attenuated) virus within 28 days of screening or intend to receive during the course of the study

• Atopic dermatitis participants:

  • Must not have received certain topical medications for AD within 2 weeks prior to randomization
  • Must not have received certain oral medications for AD or received phototherapy within 4 weeks prior to randomization
  • Must not have received any antibody-based biologic agents (marketed or investigational) within 5 half lives (t1/2) of the drug prior to randomization
  • Must not have received intravenous, intramuscular, or intra-articular steroids in the past 6 weeks prior to randomization

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LY3844583 (Part A); Single doses of LY3844583 administered subcutaneously (SC) and/or intravenously (IV).	Drug: LY3844583; Administered SC and/or IV.
Experimental: LY3844583 (Part B); Multiple doses of LY3844583 administered SC and/or IV.	Drug: LY3844583; Administered SC and/or IV.
Experimental: LY3844583 (Part C); Repeat doses of LY3844583 administered SC and/or IV.	Drug: LY3844583; Administered SC and/or IV.
Placebo Comparator: Placebo (Part A); Placebo administered SC and/or IV.	Drug: Placebo; Administered SC and/or IV.
Placebo Comparator: Placebo (Part B); Placebo administered SC and/or IV.	Drug: Placebo; Administered SC and/or IV.
Placebo Comparator: Placebo (Part C); Placebo administered SC and/or IV.	Drug: Placebo; Administered SC and/or IV.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with One or More Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of AEs, TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module	Baseline up to Day 186

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583	PK: Cmax of LY3844583	Pre-dose on Day 1 up to 186 days post-dose
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3844583	PK: AUC of LY3844583	Pre-dose on Day 1 up to 186 days post-dose

Collaborators and Investigators

• Sponsor: Eli Lilly and Company
• Investigators: Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

Helpful Links

• A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Study record dates

Study Major Dates

• Study Start (Actual): August 11, 2022
• Primary Completion (Actual): January 20, 2024
• Study Completion (Actual): January 20, 2024

Study Registration Dates

• First Submitted: August 2, 2022
• First Submitted That Met QC Criteria: August 2, 2022
• First Posted (Actual): August 3, 2022

Study Record Updates

• Last Update Posted (Estimated): January 25, 2024
• Last Update Submitted That Met QC Criteria: January 24, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Dermatitis, Atopic
• Other Study ID Numbers: 18365; J3V-MC-KKAA (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No